Associate Professor Murdoch University Kardinya, Western Australia, Australia
Disclosure(s):
Claire R. Sharp, BVMS(Hons), MS, DACVECC: No financial relationships to disclose
This session will apply the CURATIVE guidelines to specific case scenarios beyond those which the CURATIVE authors have already published. Specifically IMHA in a dog with marked thrombocytopenia that goes on to require therapeutic plasma exchange, aortic thromboembolism in a cat, as well as some more complicated cases with systemic disease. For each scenario we will determine whether the patient is at high risk vs. low/moderate risk of thrombosis, choose an appropriate anticoagulant and/or antiplatelet drug (or both), select an appropriate dose, route, and frequency, determine whether or not therapeutic monitoring is indicated, and consider the appropriate duration of therapy.
Learning Objectives:
Apply evidence-based recommendations to select appropriate antithrombotic or thrombolytic strategies for dogs and cats with high-risk conditions such as IMHA, cardiomyopathy, and protein-losing nephropathy.
Perform a risk assessment of patient-specific thrombotic risk factors and comorbidities in complex cases, including those requiring advanced interventions like extracorporeal therapies.
Justify therapeutic choices of antithrombotic and thrombolytic medications by considering guideline-based dosing, monitoring, and potential complications when managing arterial and venous thromboembolism in dogs and cats.
